Skip to main content
. 2017 Aug 2;8(39):66087–66097. doi: 10.18632/oncotarget.19798

Figure 4. The impact of RAS abnormalities on overall survival in AML patients.

Figure 4

(A, B and C) For KRAS abnormalities in whole-cohort AML, non-APL AML, and CN-AML patients. (D, E and F) For NRAS abnormalities in whole-cohort AML, non-APL AML, and CN-AML patients. (G, H and I) For RAS abnormalities in whole-cohort AML, non-APL AML, and CN-AML patients. “Abnormal” indicated gene with overexpression or mutation, whereas “normal” indicated gene without overexpression and mutation.